Peptide profile · Weight Management
Survodutide
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
3.6 mg
Half-life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
Molecular weight
4,231.6 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C192H289N47O61
Primary benefits
Up to 14.9% weight loss at 46 weeks through dual GLP-1R and GCGR activation — enhancing both appetite suppression and energy expenditure beyond GLP-1 alone
62% MASH resolution rate at optimal dose, significant hepatic fat reduction, and comprehensive metabolic improvements including glycemic control and lipid profiles
HbA1c reductions up to 1.71% in type 2 diabetes with greater weight loss than semaglutide at equivalent glycemic efficacy
Roche / Carmot Therapeutics (Novo Nordisk partnership)
Amino acid sequence
Modified GLP-1/Glucagon-analogue fusion02 · Dosing
How much do I take?
3.6 mg · once weekly
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Survodutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Survodutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Survodutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for significant body weight reduction in obesity & mash/nash resolution and liver fibrosis improvement
Best for
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Survodutide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
subcutaneous injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Survodutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Survodutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Survodutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Survodutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 2 serious
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Phase 2 trial safety data in ~400 patients supports tolerability for up to 48 weeks, though long-term data beyond 1 year remains limited prior to potential regulatory approval. Cardiovascular outcome trials and long-term hepatic safety monitoring in MASH population are ongoing. Not yet FDA-approved—all use remains investigational pending Phase 3 completion.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Survodutide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Survodutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Metformin — Complementary insulin-sensitizing mechanism with established cardiovascular benefits supports comprehensive metabolic management
- ✓SGLT2 Inhibitors — Independent glucose-lowering and cardiorenal protective mechanisms complement survodutide's metabolic and hepatic benefits
- ✓Dietary Intervention — Caloric restriction synergizes with survodutide's appetite suppression and enhanced energy expenditure for maximal weight loss
With medications
- !Other GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- !Insulin Secretagogues — Increased hypoglycemia risk when combined with agents that stimulate insulin secretion independent of glucose levels
- !Glucagon for Hypoglycemia Rescue — Survodutide's glucagon receptor agonism may alter the pharmacodynamics of exogenous glucagon used in hypoglycemia emergencies
With supplements
- ✓Multivitamins — Generally safe to take alongside Survodutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-16
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Survodutide is a dual GLP-1/glucagon receptor agonist designed to deliver even stronger weight loss and metabolic benefits than single-hormone drugs by activating two appetite and metabolism control pathways simultaneously.
Survodutide is a potent dual GLP-1/glucagon receptor agonist engineered to activate both the GLP-1 receptor (promoting insulin secretion and appetite suppression) and the glucagon receptor (promoting energy expenditure and hepatic glucose metabolism). The dual activation amplifies weight loss through complementary mechanisms: GLP-1 suppresses appetite and slows gastric emptying while glucagon increases energy expenditure, elevates metabolic rate through activation of brown adipose tissue thermogenesis, and promotes hepatic fat oxidation—collectively producing synergistic metabolic improvements exceeding single-hormone agonists.
What to expect
Weeks 1-16
What you might notice
- •Dose escalation period with gradual introduction
- •GI side effects (nausea, vomiting) are most common during this phase
- •Early appetite reduction and beginning of weight loss
What's normal
- •Nausea is expected and typically peaks during dose increases
- •Appetite reduction begins early
- •Weight loss starts but accelerates as maintenance dose is reached
- •GI symptoms generally improve with continued dosing
What's next
- →Complete dose escalation to target maintenance dose (3
- →0 mg weekly)
- →GI tolerability typically improves as the body adjusts to each dose level
Weeks 16-32
What you might notice
- •Accelerating weight loss at maintenance dose
- •Improved glycemic markers if diabetic
- •GI side effects diminishing
- •Measurable improvements in metabolic parameters
What's normal
- •Steady weight loss trajectory
- •HbA1c improvements in diabetic patients
- •Liver enzyme improvements in MASH patients
- •Reduced appetite stabilizes
- •GI side effects become less frequent
What's next
- →Continue maintenance dosing
- →Clinical assessment of weight loss, metabolic parameters, and liver health markers
Weeks 32-52+
What you might notice
- •Continued weight loss approaching 10-15% of body weight
- •Sustained metabolic improvements
- •In MASH patients, potential histological improvement on liver biopsy
What's normal
- •Weight loss may continue beyond 46 weeks (Phase 2 data suggested ongoing trajectory)
- •Metabolic parameters remain improved
- •Weight loss rate may gradually slow as new steady state is approached
What's next
- →Long-term maintenance therapy
- →Phase 3 trials evaluating 76-week outcomes will define long-term efficacy and safety profile
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Survodutide over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
How does survodutide differ from semaglutide and other GLP-1 agonists?+
Survodutide is a dual agonist that activates both the GLP-1 receptor AND the glucagon receptor, while semaglutide only activates the GLP-1 receptor. The glucagon receptor component adds a fundamentally different mechanism — it increases energy expenditure, stimulates hepatic fat oxidation, and promotes thermogenesis. In head-to-head Phase 2 comparison, survodutide produced greater weight loss (8.7% vs 5.3%) than semaglutide at equivalent glycemic control in type 2 diabetes patients.
What is the MASH breakthrough therapy designation?+
The FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. This was based on Phase 2 data showing 62% of patients achieved MASH resolution without worsening fibrosis at the 4.8 mg dose, compared to only 14% with placebo. This designation accelerates the development and regulatory review process.
When might survodutide become commercially available?+
Survodutide is currently in Phase 3 clinical trials. The SYNCHRONIZE obesity program and LIVERAGE MASH program are expected to report results in 2026-2027. Regulatory submissions could follow positive Phase 3 results, with potential approval estimated for 2027-2028, though timelines depend on trial outcomes and regulatory review.
Why does survodutide cause more GI side effects than some other treatments?+
Survodutide stimulates both GLP-1 and glucagon receptors in the gastrointestinal tract and central nervous system, resulting in more pronounced effects on gut motility, gastric emptying, and appetite signaling compared to GLP-1-only agonists. Nausea occurred in up to 75% of patients versus 42% on placebo. However, gradual dose escalation over 16-20 weeks significantly mitigates these effects, and most patients tolerate the medication well at maintenance doses.
Is the glucagon component of survodutide safe for diabetic patients?+
Yes, the glucagon receptor agonism does not worsen glycemic control because it is balanced by the GLP-1 receptor component which promotes glucose-dependent insulin secretion. In Phase 2 diabetes trials, survodutide achieved comparable HbA1c reduction to semaglutide while providing superior weight loss. The dual agonism appears metabolically synergistic rather than antagonistic.
What Phase 3 trials are currently running?+
Several Phase 3 programs are underway: SYNCHRONIZE-1 (obesity without diabetes, n=726), SYNCHRONIZE-2 (obesity with T2DM, n=755), SYNCHRONIZE-CVOT (cardiovascular outcomes, n=5,531), LIVERAGE (MASH with fibrosis, n=1,800), and regional trials in China and Japan. These represent one of the largest clinical development programs for a metabolic disease agent.
08 · Further reading
History & related research
History · since 2017
The Dual-Power Drug That Breaks the Glucagon Taboo
For decades, doctors feared glucagon — the hormone that raises blood sugar. But one team at Boehringer Ingelheim asked a revolutionary question: What if we ADDED glucagon instead of blocking it?
Read the full history of Survodutide